Completed PHASE3 INTERVENTIONAL 2-arm NCT02586311

CKD-330 Phase 3 Trial in Amlodipine Non-responder

A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a CKD-330 Versus Amlodipine Monotherapy in Hypertensive Patients Inadequately Controlled by Amlodipine Monotherapy

Sponsor: Chong Kun Dang Pharmaceutical

Conditions Hypertension

Interventions Amlodipine 5mg Amlodipine 5mg Placebo CKD-330 16/5mg CKD-330 16/5mg Placebo

Updated 6 times since 2017 Last updated: Oct 4, 2016 Started: Jan 31, 2016 Primary completion: Aug 31, 2016 Completion: Sep 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02586311, this PHASE3 trial focuses on Hypertension and remains completed. Sponsored by Chong Kun Dang Pharmaceutical, it has been updated 6 times since 2016, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chong Kun Dang Pharmaceutical

Data source: Chong Kun Dang Pharmaceutical

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea